primary acquired resistance colorectal cancer cells anti-egfr antibodies converge mek/erk pathway activation overcome pubmed ncbi abstract purpose egfr-independent activation ras/raf/mek/mapk pathway resistance mechanisms cetuximab experimental design evaluated vitro vivo effects bay num selective mek num inhibitor panel human colorectal cancer cell lines primary acquired resistance cetuximab results colorectal cancer cell lines kras mutation lovo hct num hct num sw num sw num braf mutation ht num resistant antiproliferative effects cetuximab cells geo sw num highly sensitive treatment bay num determined dose-dependent growth inhibition cancer cells including human colorectal cancer cells acquired resistance cetuximab geo-cr sw num cr exception hct num cells combined treatment cetuximab bay num induced synergistic antiproliferative apoptotic effects blockade mapk akt pathway cells primary acquired resistance cetuximab synergistic antiproliferative effects confirmed selective mek num inhibitors selumetinib pimasertib combination cetuximab inhibition mek expression sirna restored cetuximab sensitivity resistant cells nude mice bearing established human hct num hct num sw num cr geo-cr xenografts combined treatment cetuximab bay num caused significant tumor growth inhibition increased mice survival conclusion results suggest activation mek involved primary acquired resistance cetuximab inhibition egfr mek strategy overcoming anti-egfr resistance patients colorectal cancer num american association cancer research 
